Geneyx operates in the genetic data analysis and clinical genome research market, serving hospitals, labs, and clinicians globally. The company offers a platform for Next-Generation Sequencing (NGS) data analysis and interpretation, specifically for Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), and Gene Panels. Geneyx's platform reduces the time associated with analysis, interpretation, and reporting by 95% through a streamlined, automated workflow. This automation decreases overhead costs and requires less hands-on time, making the process more efficient and cost-effective. The platform also increases diagnostic yield and empowers clinicians with rapid clinical decision support, thereby accelerating the diagnostic process from raw genetic data to clinical reports. Geneyx utilizes the largest unified global knowledge base for interrogating genetic-based diseases and disorders, ensuring high accuracy and up-to-date information. The business model revolves around providing a subscription-based service to medical institutions, generating revenue through recurring fees. The company also focuses on reducing liability for clinical providers by offering auditable, evidence-based reports.

Keywords: Genetic Data Analysis, Clinical Genome Research, NGS, WGS, WES, Gene Panels, Automation, Diagnostic Yield, Machine Learning, Bioinformatics.